Tissue-specific promoters for cancer gene therapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 683-696

  Saukkonen, Kirsi ^a   Hemminki, Akseli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adenovirus; Cancer; Gene therapy; Promoter; Targeting; Tissue specific

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CONDITIONALLY REPLICATING ADENOVIRUS; CV 706; CYCLOOXYGENASE 2; L PLASTIN; ONYX 015; OSTEOCALCIN; PRODRUG; PRODRUG CONVERTING ENZYME; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TELOMERASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENE THERAPY; GENETIC TRANSDUCTION; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; REVIEW; TISSUE SPECIFIC PROMOTER; TISSUE SPECIFICITY; TOXICITY; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS);

ADENOVIRIDAE;

EID: 2442713854     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.683     Document Type: Review

References (136)

1. HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. (2002) 346:1185-1193.
2. AIUTI A, SLAVIN S, AKER M et al.: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296:2410-2413.
3. POWELL JS, RAGNI MV, WHITE GC et al.: Phase I trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102:2038-2045.
4. HEMMINKI A: From molecular changes to customised therapy. Eur. J. Cancer (2002) 38:333-338.
5. KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6:879-885.
6. NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. (2001) 8:746-759.
7. SANDMAIR AM, LOIMAS S, PURANEN P et al.: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. (2000) 11:2197-2205.
8. SCHULER M, HERRMANN R, DE GREVE JL et al.: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol. (2001) 19:1750-1758.
9. LUNDSTROM K: Latest development in viral vectors for gene therapy. Trends Biotechnol. (2003) 21:117-122.
10. RAINOV NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11:2389-2401.
11. KLATZMANN D, VALERY CA, BENSIMON G et al.: A Phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther. (1998) 9:2595-2604.
12. SHAND N, WEBER F, MARIANI L et al.: A Phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10:2325-2335.
13. PRADOS MD, MCDERMOTT M, CHANG SM et al.: Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J Neurooncol. (2003) 65:269-278.
14. VENDITTI G, DI IANNI M, FALZETTI F, MORETTI L, DI FLORIO S, TABILIO A: NeoR-based transduced T lymphocytes detected by real-time quantitative polymerase chain reaction. J. Hematother. Stem Cell Res. (2003) 12:83-91.
15. WANG WJ, TAI CK, KASAHARA N, CHEN TC: Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther. (2003) 14:117-127.
16. MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther (2000) 7:867-874.
17. MA HI, GUO P, LI J et al.: Suppression of intractanial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. (2002) 62:756-763.
18. CRIPE TP, DUNPHY EJ, HOLUB AD et al.: Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. (2001) 61:2953-2960.
19. FECHNER H, WANG X, WANG H et al.: Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. (2000) 7:1954-1968.
20. HUTCHIN ME, PICKLES RJ, YARBROUGH WG: Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum. Gene Ther. (2000) 11:2365-2375.
21. LI Y, PONG RC, BERGELSON JM et al.: Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. (1999) 59:325-330.
22. MILLER CR, BUCHSBAUM DJ, REYNOLDS PN et al.: Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. (1998) 58:5738-5748.
23. MORI T, ARAKAWA H, TOKINO T, MINEURA K, NAKAMURA Y: Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR. Oncol. Res. (1999) 11:513-521.
24. NALBANTOGLU J, LAROCHELLE N, WOLF E, KARPATI G, LOCHMULLER H, HOLLAND PC: Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle. J. Virol. (2001) 75:4276-4282.
25. BAUERSCHMITZ GJ, BARKER SD, HEMMINKI A: Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int. J. Oncol. (2002) 21:1161-1174.
26. HONG SS, KARAYAN L, TOURNIER J, CURIEL D T, BOULANGER PA: Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. (1997) 16:2294-2306.
27. SMITH TA, IDAMAKANTI N, MARSHALL-NEFF J et al.: Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. (2003) 14:1595-1604.
28. DMITRIEV I, KRASNYKH V, MILLER CR et al.: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilisation of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. (1998) 72:9706-9713. Landmark paper in genetic retargeting of adenoviruses.
29. HEMMI S, GEERTSEN R, MEZZACASA A, PETER I, DUMMER R: The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. (1998) 9:2363-2373.
30. KASONO K, BLACKWELL JL, DOUGLAS JT et al.: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. (1999) 5:2571-2579.
31. KELLY FJ, MILLER CR, BUCHSBAUM DJ et al.: Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. (2000) 6:4323-4333.
32. OKEGAWA T, LI Y, PONG RC, BERGELSON JM, ZHOU J, HSIEH JT: The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. (2000) 60:5031-5036.
33. OKEGAWA T, PONG RC, LI Y, BERGELSON JM, SAGALOWSKY AI, HSIEH JT: The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res. (2001) 61:6592-6600.
34. RAUEN KA, SUDILOVSKY D, LE JL et al.: Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. (2002) 62:3812-3818.
35. ZEIMET A G, MULLER-HOLZNER E, SCHULER A et al.: Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. (2002) 9:1093-1100.
36. HEMMINKI A, DMITRIEV I, LIU B, DESMOND RA, ALEMANY R, CURIEL DT: Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. (2001) 61:6377-6381.
37. KANERVA A, MIKHEEVA GV, KRASNYKH V et al.: Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. (2002) 8:275-280.
38. KANERVA A, WANG M, BAUERSCHMITZ GJ et al.: Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. (2002) 5:695-704.
39. KANERVA A, ZINN KR, CHAUDHURI TR et al.: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. (2003) 8:449-458.
40. ANDERS M, CHRISTIAN C, MCMAHON M, MCCORMICK F, KORN WM: Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. (2003) 63:2088-2095.
41. HEMMINKI A, ALVAREZ RD: Adenoviruses in oncology: a viable option? Biodrugs (2002) 16:77-87.
42. SHINOURA N, MURAMATSU Y, NISHIMURA M et al.: Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res. (1999) 59:5521-5528.
43. DOUGLAS JT, KIM M, SUMEREL LA, CAREY DE, CURIEL DT: Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. (2001) 61:813-817.
44. GAHERY-SEGARD H, MOLINIER-FRENKEL V, LE BOULAIRE C et al.: Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. (1997) 100:2218-2226.
45. GAHERY-SEGARD H, FARACE F, GODFRIN D et al.: Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. (1998) 72:2388-2397.
46. MOLINIER-FRENKEL V, LE BOULAIRE C, LE GAL FA et al.: Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum. Gene Ther. (2000) 11:1911-1920.
47. YOUNG LS, MAUTNER V: The promise and potential hazards of adenovirus gene therapy. Gut (2001) 48:733-736.
48. RAPER SE, CHIRMULE N, LEE FS et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenovital gene transfer. Mol. Genet. Metab. (2003) 80:148-158.
49. SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1999) 91:763-771.
50. SWISHER SG, ROTH JA, KOMAKI R et al.: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. (2003) 9:93-101.
51. WILSON WR, PULLEN SM, HOGG A, HOBBS SM, PRUIJN FB, HICKS KO: In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. Methods Mol. Med. (2004) 90:403-432.
52. FREYTAG SO, KHIL M, STRICKER H et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. (2002) 62:4968-4976. First clinical study to investigate the combination of CRADs with molecular chemotherapy.
53. WILDNER O: Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr. Opin. Mol. Ther. (2003) 5:351-361.
54. SAUTER BV, MARTINET O, ZHANG WJ, MANDELI J, WOO SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA (2000) 97:4802-4807.
55. SAVONTAUS MJ, SAUTER BV, HUANG TG, WOO SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. (2002) 9:972-979.
56. MAZZOLINI G, PRIETO J, MELERO I: Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. (2003) 9:1981-1991.
57. KOENEMAN KS, KAO C, KO SC et al.: Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. (2000) 18:102-110.
58. SCHULER M, ROCHLITZ C, HOROWITZ JA et al.: A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. (1998) 9:2075-2082.
59. HEMMINKI A, ZINN KR, LIU B et al.: In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J. Natl. Cancer Inst. (2002) 94:741-749. A new generation Ad for imaging and molecular chemotherapy.
60. HEMMINKI A, BELOUSOVA N, ZINN KR et al.: An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. (2001) 4:223-231.
61. ALEMANY R, BALAGUE C, CURIEL DT: Replicative adenoviruses for cancer therapy. Nat. Biotechnol. (2000) 118:723-727.
62. HEISE C, KIRN DH: Replication-selective adenoviruses as oncolytic agents J. Clin. Invest. (2000) 105:847-851.
63. KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. (2001) 7:781-787.
64. SINKOVICS J, HORVATH J: New developments in the virus therapy of cancer: a historical review. Intervirology (1993) 36:193-214.
65. SMITH RR, HUEBNER RJ, ROWE WP, SCHATTEN WE, THOMAS LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1956) 9:1211-1218.
66. BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373-376. First CRAD.
67. DIX BR, EDWARDS SJ, BRAITHWAITE AW: Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J. Virol. (2001) 75:5443-5447.
68. RIES SJ, BRANDTS CH, CHUNG AS et al.: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. (2000) 6:1128-1133.
69. EDWARDS SJ, DIX BR, MYERS CJ et al.: Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J. Virol. (2002) 76:12483-12490.
70. NEMUNAITIS J, KHURI F, GANLY I et al.: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. (2001) 19:289-298.
71. KIRN D: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. (2001) 8:89-98.
72. NETTELBECK DM, JEROME V, MULLER R: Gene therapy: designer promoters for tumour targeting. Trends Genet. (2000) 16:174-181.
73. SAUKKONEN K, RINTAHAKA J, SIVULA A et al.: Cyclooxygenase-2 and gastric carcinogenesis. APMIS (2003) 111:915-925.
74. YAMAMOTO M, ALEMANY R, ADACHI Y, GRIZZLE WE, CURIEL DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol. Ther. (2001) 3:385-394.
75. CASADO E, GOMEZ-NAVARRO J, YAMAMOTO M et al.: Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin. Cancer Res. (2001) 7:2496-2504.
76. WESSELING JG, YAMAMOTO M, ADACHI Y et al.: Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. (2001) 8:990-996.
77. YAMAMOTO M, DAVYDOVA J, WANG M et al.: Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 125:1203-1218.
78. KANERVA A, BAUERSCHMITZ GJ, YAMAMOTO M et al.: A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. (2004) 11:552-559.
79. MEYERSON M, COUNTER CM, EATON EN et al.: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 90:785-795.
80. HARLEY CB, KIM NW, PROWSE K et al.: Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. (1994) 59:307-315.
81. KIM NW, PIATYSZEK MA, PROWSE KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 266:2011-2015.
82. HUANG TG, SAVONTAUS MJ, SHINOZAKI K, SAUTER BV, WOO SL: Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. (2003) 10:1241-1247.
83. LANSON NA, FRIEDLANDER PL, SCHWARZENBERGER P, KOLLS JK, WANG G: Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. (2003) 63:7936-7941.
84. WIRTH T, ZENDER L, SCHULTE B et al.: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. (2003) 63:3181-3188.
85. HAMMARSTROM S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. (1999) 9:67-81.
86. TANAKA T, KANAI F, OKABE S et al.: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. (1996) 56:1341-1345.
87. OSAKI T, TANIO Y, TACHIBANA I et al.: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. (1994) 54:5258-5261.
88. TANAKA T, KANAI F, LAN KH et al.: Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem. Biophys. Res. Commun. (1997) 231:775-779.
89. LAN KH, KANAI F, SHIRATORI Y et al.: In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. (1997) 57:4279-4284.
90. BRAND K, LOSER P, ARNOLD W, BARTELS T, STRAUSS M: Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther. (1998) 5:1363-1371.
91. LI Y, CHEN Y, DILLEY J et al.: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer. Ther. (2003) 2:1003-1009.
92. HUANG X, ZHANG W, WAKIMOTO H, HAMADA H, CAO X: Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. J. Exp. Ther. Oncol. (2002) 2:100-106.
93. KANAI F, LAN KH, SHIRATORI Y et al.: In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. (1997) 57:461-465.
94. LIN CS, CHEN ZP, PARK T, GHOSH K, LEAVITT J: Characterization of the human L-plastin gene promoter in normal and neoplastic cells. J. Biol. Chem. (1993) 268:2793-2801.
95. CHUNG I, SCHWARTZ PE, CRYSTAL RG, PIZZORNO G, LEAVITT J, DEISSEROTH AB: Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. (1999) 6:99-106.
96. PENG XY, WON JH, RUTHERFORD T et al.: The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. (2001) 61:4405-4413.
97. ZHANG L, AKBULUT H, TANG Y et al.: Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol. Ther. (2002) 6:386-393.
98. ABE T, TOMINAGA Y, KIKUCHI T et al.: Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung. Am. J. Respir. Crit. Care Med. (1997) 156:1235-1240.
99. BARKER SD, COOLIDGE CJ, KANERVA A et al.: The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J. Gene Med. (2003) 5:300-310. Example of the preclinical development needed for characterisation of TSPs.
100. SHIRAKAWA T, GOTOH A, WADA Y et al.: Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol. Urol. (2000) 4:73-82.
101. HSIEH CL, YANG L, MIAO L et al.: A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Cancer Res. (2002) 62:3084-3092.
102. CAM H, DYNLACHT BD: Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell (2003) 3:311-316.
103. HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus E1A mutant that demonstrates potent and selective systemic and-tumoral efficacy. Nat. Med. (2000) 6:1134-1139.
104. BAUERSCHMITZ GJ, LAM JT, KANERVA A et al.: Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. (2002) 62:1266-1270.
105. JAKUBCZAK JL, RYAN P, GORZIGLIA M et al.: An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. (2003) 63:1490-1499.
106. JOHNSON L, SHEN A, BOYLE L et al.: Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1:325-337.
107. FRIEDMAN EL, HAYES DF, KUFE DW: Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. (1986) 46:5189-5194.
108. HO SB, NIEHANS GA, LYFTOGT C et al.: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. (1993) 53:641-651.
109. KURIHARA T, BROUGH DE, KOVESDI I, KUFE DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. (2000) 106:763-771.
110. WALTON T, WANG JL, RIBAS A, BARSKY SH, ECONOMOU J, NGUYEN M: Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anti-Cancer Res. (1998) 18:1357-1360.
111. VARDA-BLOOM N, SHAISH A, GONEN A et al.: Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. (2001) 8:819-827.
112. SAVONTAUS MJ, SAUTER BV, HUANG TG, WOO SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. (2002) 9:972-979.
113. PETER I, GRAF C, DUMMER R, SCHAFFNER W, GREBER UF, HEMMI S: A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Ther. (2003) 10:530-539.
114. STEINER MS, ANTHONY CT, LU Y, HOLT JT: Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Ther. (1998) 9:747-755.
115. HERNANDEZ-ALCOCEBA R, PIHALJA M, WICHA MS, CLARKE MF: A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum. Gene Ther. (2000) 11:2009-2024.
116. WALTHER W, WENDT J, STEIN U: Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther. (1997) 4:544-552.
117. CHAUDHURI TR, CAO Z, KRASNYKH VN et al.: Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts. Technol. Cancer Res. Treat. (2003) 2:171-180.
118. DINGLI D, RUSSELL SJ, MORRIS JC: In vivo imaging and tumor therapy with the sodium iodide symporter. J. Cell. Biochem. (2003) 90:1079-1086.
119. ADAMS JY, JOHNSON M, SATO M et al.: Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. (2002) 8:891-897. Exciting developments in utilisation of TSPs for detection of metastases.
120. WHITE RE, WADE-MARTINS R, HART SL et al.: Functional delivery of large genomic DNA to human cells with a peptide-lipid vector. J. Gene Med. (2003) 5:883-892.
121. HAMID O, VARTERASIAN ML, WADLER S et al.: Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:1498-1504.
122. DEWEESE TL, VAN DER POEL H, LI S et al.: A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. (2001) 61:7464-7472.
123. KUBO H, GARDNER TA, WADA Y et al.: Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. (2003) 14:227-241.
124. FREYTAG SO, STRICKER H, PEGG J et al.: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res. (2003) 63:7497-7506. First clinical study to investigate the combination of CRADs, molecular chemotherapy and radiation therapy.
125. SUZUKI K, FUEYO J, KRASNYKH V, REYNOLDS PN, CURIEL DT, ALEMANY R: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. (2001) 7:120-126.
126. VOLK AL, RIVERA AA, KANERVA A et al.: Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol. Ther. (2003) 2:511-515.
127. NEMUNAITIS J, GANLY I, KHURI F et al.: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. (2000) 60:6359-6366.
128. LAMONT JP, NEMUNAITIS J, KUHN JA, LANDERS SA, MCCARTY TM: A prospective Phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squarnous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. (2000) 7:588-592.
129. GANLY I, KIRN D, ECKHARDT G et al.: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. (2000) 6:798-806.
130. REID T, GALANIS E, ABBRUZZESE J et al.: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. (2001) 8:1618-1626.
131. MULVIHILL S, WARREN R, VENOOK A et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. (2001) 8:308-315.
132. REID T, GALANIS E, ABBRUZZESE J et al.: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. (2002) 62:6070-6079.
133. VASEY PA, SHULMAN LN, CAMPOS S et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. (2002) 20:1562-1569.
134. MAKOWER D, ROZENBLIT A, KAUFMAN H et al.: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. (2003) 9:693-702.
135. HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9:555-561.
136. LI S, SIMONS J, DETORIE N, O'ROURKE B, HAMPER U, DEWEESE TL: Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (2003) 55:204-214.